- Ongoing actions to support its members, providers, employees,
and communities during the COVID-19 pandemic, including the
donation of an additional $150 million to the Humana Foundation to
address social determinants of health in an effort to promote more
healthy days and encourage greater health equity
- Reports 2Q20 earnings per diluted common share (EPS) of $13.75
on a GAAP basis, $12.56 on an Adjusted basis; reports YTD 2020 EPS
of $17.31 on a GAAP basis, $17.97 on an Adjusted basis
- Comments on FY 2020 guidance:
- FY 2020 GAAP EPS expected to be in a range of $17.36 to
$17.86
- Reaffirms FY 2020 Adjusted EPS guidance range of $18.25 to
$18.75 while acknowledging the inherent uncertainty surrounding the
ongoing pandemic
- Increases full year expected individual Medicare Advantage
membership growth to 330,000 to 360,000 members from previous range
of 300,000 to 350,000 members
During the second quarter of 2020, Humana Inc. (NYSE: HUM)
continued to take actions to protect, inform, and care for its
members, providers, employees, and other stakeholders during the
COVID-19 crisis. Specifically, Humana took the following actions to
support its members:
- waiving all cost sharing for in-network primary care,
outpatient behavioral health, and telehealth visits for the
remainder of 2020 for its Medicare Advantage members, to reduce
financial barriers to members seeking to re-engage with their
providers, while continuing to encourage the use of
telehealth;
- making it easier for members to be tested for COVID-19 by
offering a pilot at-home testing program, as well as collaborating
with other providers to deploy drive-thru testing at hundreds of
sites throughout the country;
- mailing in-home screening kits to members, to encourage members
to seek preventive care that may have been delayed during the
pandemic;
- proactively delivering safety kits, including face masks, to
member and employee homes to facilitate access to care and support
visits to providers safely;
- continuing to extend grace periods for premium payments for its
fully-insured commercial group members, to ensure continuity of
coverage during times of financial stress; and
- providing a concierge line dedicated to COVID-19 related
inquires.
In addition, Humana took steps to support its provider partners
and boost system viability:
- expanding modifications to certain utilization management
processes, to ease administrative stress and make sure providers
are able to most efficiently care for their patients; and
- simplifying and expediting claims processing and releasing
approximately $1 billion in advanced funding to providers, to get
reimbursement payments to providers as quickly as possible and ease
financial concerns so that members are able to continue to access
the care and information they need.
Finally, Humana continued to support the communities it serves
by donating $200 million ($150 million during the second quarter)
to the Humana Foundation to address social determinants of health
in an effort to promote more healthy days and encourage greater
health equity.
Humana's second quarter results of operations were materially
impacted by the significant, temporary deferral of care resulting
from stay-at-home orders, physical distancing measures, and other
restrictions on movement and economic activity implemented
throughout the country to reduce the spread of COVID-19. Hospital
admissions and utilization were significantly depressed in April,
increased throughout May and June, and remained modestly below
normal at the close of the quarter. The impact of the deferral of
care on second quarter results was partially offset by COVID-19
testing and treatment costs, as well as the company's ongoing
pandemic relief efforts.
Humana anticipates its second quarter results will be offset in
the latter half of 2020 as demand for previously deferred care
normalizes, combined with the financial impact of the company's
ongoing relief efforts to ease the burden of the pandemic for its
constituents, which is heavily weighted to the second half of 2020.
As the COVID-19 pandemic progresses, Humana will continue to
monitor the impact on the company and all of its stakeholders and
adjust its response accordingly, proactively leveraging its
integrated care delivery model to best serve its members,
partnering with federal and state governments to develop
comprehensive and actionable response plans, minimizing the impact
on its provider partners, and advancing the long-term
sustainability of the company and the healthcare system.
“As we continue to navigate the global coronavirus pandemic,
Humana is committed to ongoing investments in benefits and
initiatives designed to improve access to care and ease the
financial burden for our members, employer groups and providers,”
said Bruce D. Broussard, Humana’s President and Chief Executive
Officer. “We remain focused on being responsive to our member and
patient needs and providing convenient and safe choices of care.
Among many preventive clinical interventions, we are distributing 1
million in-home screening kits to members. Members can also engage
with nurse practitioners and primary care physicians in the home,
or via telehealth, to identify and address gaps in care. These
measures are increasing access to preventive and routine care that
many members have delayed during the pandemic, ensuring proper
diagnoses and improved clinical outcomes.”
Summary of Quarterly and Year to Date
Results
Humana today reported consolidated pretax income and diluted
earnings per common share (EPS) for the quarter ended June 30, 2020
(2Q20) versus the quarter ended June 30, 2019 (2Q19) and for the
six months ended June 30, 2020 (YTD 2020) versus the six months
ended June 30, 2019 (YTD 2019) as follows.
Consolidated income before income taxes
and equity in earnings (pretax
income) In millions
2Q20 (a)
2Q19 (b)
YTD 2020 (c)
YTD 2019 (d)
Generally Accepted Accounting
Principles (GAAP)
$2,586
$1,229
$3,303
$1,975
Amortization associated with identifiable
intangibles
22
18
43
36
Put/call valuation adjustments associated
with company's non-consolidating
minority interest investments
(227)
(174)
70
(135)
Adjusted (non-GAAP)
$2,381
$1,073
$3,416
$1,876
Diluted earnings per common share
(EPS)
2Q20 (a)
2Q19 (b)
YTD 2020 (c)
YTD 2019 (d)
GAAP
$13.75
$6.94
$17.31
$11.10
Amortization associated with identifiable
intangibles
0.13
0.10
0.26
0.20
Put/call valuation adjustments associated
with company's non-consolidating
minority interest investments
(1.32)
(0.99)
0.40
(0.77)
Adjusted (non-GAAP)
$12.56
$6.05
$17.97
$10.53
The company has included financial measures throughout this
earnings release that are not in accordance with GAAP. Management
believes that these measures, when presented in conjunction with
the comparable GAAP measures, are useful to both management and its
investors in analyzing the company’s ongoing business and operating
performance. Consequently, management uses these non-GAAP
(Adjusted) financial measures as indicators of the company’s
business performance, as well as for operational planning and
decision making purposes. Non-GAAP (Adjusted) financial measures
should be considered in addition to, but not as a substitute for,
or superior to, financial measures prepared in accordance with
GAAP. All financial measures in this press release are in
accordance with GAAP unless otherwise indicated. Please refer to
the footnotes for a detailed description of each item adjusted out
of GAAP financial measures to arrive at a non-GAAP (Adjusted)
financial measure.
Please refer to the tables above, as well as the consolidated
and segment highlight sections in the detailed earnings release for
additional discussion of the factors impacting the
year-over-comparisons.
In addition, below is a summary of key consolidated and segment
statistics comparing 2Q20 to 2Q19 and YTD 2020 to YTD 2019.
Humana Inc. Summary of Quarterly
Results
(dollars in millions, except per share
amounts)
2Q20 (a)
2Q19 (b)
YTD 2020 (c)
YTD 2019 (d)
Consolidated results:
Revenues - GAAP
$19,083
$16,245
$38,018
$32,352
Pretax income - GAAP
$2,586
$1,229
$3,303
$1,975
Pretax income - Adjusted
$2,381
$1,073
$3,416
$1,876
EPS - GAAP
$13.75
$6.94
$17.31
$11.10
EPS - Adjusted
$12.56
$6.05
$17.97
$10.53
Benefits expense ratio - GAAP
76.4 %
84.4 %
80.7 %
85.3 %
Operating cost ratio - GAAP
12.4 %
10.6 %
11.8 %
10.5 %
Operating cash flows - GAAP
$3,067
$1,434
$3,541
$2,330
Parent company cash and short term
investments
$2,452
$1,871
Debt-to-total capitalization
35.1 %
32.5 %
Retail segment results:
Revenues - GAAP
$16,961
$14,158
$33,723
$28,171
Benefits expense ratio - GAAP
78.3 %
85.2 %
82.4 %
86.7 %
Operating cost ratio - GAAP
9.7 %
8.5 %
9.4 %
8.4 %
Segment earnings - GAAP
$1,989
$856
$2,674
$1,321
Segment earnings - Adjusted
$1,993
$860
$2,682
$1,329
Group and Specialty segment
results:
Revenues - GAAP
$1,835
$1,874
$3,700
$3,761
Benefits expense ratio - GAAP
67.0 %
86.3 %
73.1 %
81.3 %
Operating cost ratio - GAAP
23.8 %
21.7 %
23.4 %
21.8 %
Segment earnings - GAAP
$287
$5
$392
$170
Segment earnings - Adjusted
$288
$6
$394
$172
Healthcare Services segment
results:
Revenues - GAAP
$6,941
$6,387
$14,026
$12,485
Operating cost ratio - GAAP
95.1 %
96.1 %
95.6 %
96.3 %
Segment earnings - GAAP
$317
$224
$567
$399
Adjusted earnings before interest,
taxes,
depreciation and amortization (Adjusted
EBITDA) (e)
$390
$294
$709
$532
2020 Earnings Guidance
Humana is revising its GAAP EPS guidance range for the year
ending December 31, 2020 (FY 2020) to $17.36 to $17.86 from the
previous range of $16.04 to $16.54, reflecting the YTD 2020 impact
of the company's non-consolidating minority interest put/call
valuation adjustments. While acknowledging the inherent uncertainty
surrounding the ongoing crisis, Humana is maintaining its FY 2020
Adjusted EPS range of $18.25 to $18.75. For comparison, FY 2020
GAAP and Adjusted EPS guidance is detailed below along with GAAP
and Adjusted results for the year ended December 31, 2019 (FY
2019).
The company is revising its net membership growth estimate for
its individual Medicare Advantage products now expecting growth in
a range of 330,000 to 360,000 members for FY 2020 compared to the
previous guidance growth range of 300,000 to 350,000 members. This
anticipated increase in 2020 represents year-over-year growth of
approximately 10 percent at the midpoint of the guidance range.
The company is reiterating its expectations for group Medicare
Advantage net membership gains for FY 2020, projecting an increase
of approximately 90,000 members year over year.
For its stand-alone PDP business, Humana continues to estimate a
net membership decline of approximately 550,000 members for FY
2020.
Given the likelihood of significant variability of results by
financial statement line item (and related ratios), Humana
previously withdrew its additional FY 2020 detailed guidance points
that were initially provided as part of the company's fourth
quarter 2019 earnings release dated February 5, 2020.
Diluted earnings per common
share
FY 2020 Guidance
(f)
FY 2019 (g)
GAAP
$17.36 to $17.86
$20.10
Amortization of identifiable
intangibles
0.49
0.40
Put/call valuation adjustments associated
with company's non-consolidating minority interest investments
0.40
(2.89)
Charges associated with workforce
optimization
-
0.26
Adjusted (non-GAAP) – FY 2020
projected; FY 2019 reported
$18.25 to $18.75
$17.87
Detailed Press Release
Humana’s full earnings press release including the statistical
pages has been posted to the company’s Investor Relations site and
may be accessed at https://humana.gcs-web.com/ or via a current
report on Form 8-K filed by the company with the Securities and
Exchange Commission this morning (available at www.sec.gov or on
the company’s website).
Conference Call
Humana will host a conference call at 9:00 a.m. Eastern time
today to discuss its financial results for the quarter and the
company’s expectations for future earnings.
All parties interested in the company’s 2Q20 earnings conference
call are invited to dial 888-625-7430. No password is required. The
audio-only webcast of the 2Q20 earnings call may be accessed via
Humana’s Investor Relations page at humana.com. The company
suggests participants for both the conference call and those
listening via the web dial in or sign on at least 15 minutes in
advance of the call.
For those unable to participate in the live event, the archive
will be available in the Historical Webcasts and Presentations
section of the Investor Relations page at humana.com, approximately
two hours following the live webcast. Telephone replays will also
be available from approximately 12:15 p.m. Eastern time on August
5, 2020 until 10:59 p.m. Eastern time on October 4, 2020 and can be
accessed by dialing 855-859-2056 and providing the conference ID
#7379965.
Footnotes
(a) 2Q20 Adjusted results exclude the
following:
- Amortization expense for identifiable intangibles of
approximately $22 million pretax, or $0.13 per diluted common
share; GAAP measures affected in this release include consolidated
pretax, EPS, and segment earnings (for respective amortization
expense for the Retail and Group and Specialty segments).
- Put/call valuation adjustments of approximately $227 million,
or $1.32 per diluted common share, associated with Humana’s
non-consolidating minority interest investments. GAAP measures
affected in this release include consolidated pretax and EPS.
(b) 2Q19 Adjusted results exclude the
following:
- Amortization expense for identifiable intangibles of
approximately $18 million pretax, or $0.10 per diluted common
share; GAAP measures affected in this release include consolidated
pretax, EPS, and segment earnings (for respective amortization
expense for the Retail and Group and Specialty segments).
- Put/call valuation adjustments of approximately $174 million,
or $0.99 per diluted common share, associated with Humana’s
non-consolidating minority interest investments. GAAP measures
affected in this release include consolidated pretax and EPS.
(c ) YTD 2020 Adjusted results exclude the
following:
- Amortization expense for identifiable intangibles of
approximately $43 million pretax, or $0.26 per diluted common
share; GAAP measures affected in this release include consolidated
pretax, EPS and segment earnings (for respective amortization
expense for the Retail and Group and Specialty segments.
- Put/call valuation adjustments of approximately $70 million or
$0.40 per diluted common share, associated with Humana's
non-consolidating minority interest investments. GAAP measures
affected in this release include consolidated pretax and EPS.
(d) YTD 2019 Adjusted results exclude the
following:
- Amortization expense for identifiable intangibles of
approximately $36 million pretax, or $0.20 per diluted common
share; GAAP measures affected in this release include consolidated
pretax, EPS and segment earnings (for respective amortization
expense for the Retail and Group and Specialty segments.
- Put/call valuation adjustments of approximately $135 million,
or $0.77 per diluted common share, associated with Humana's
non-consolidating minority interest investments. GAAP measures
affected in this release include consolidated pretax and EPS.
(e) The Healthcare Services segment Adjusted EBITDA includes
GAAP segment earnings with adjustments to add back depreciation and
amortization expense, interest expense, and income taxes. The
Adjusted EBITDA includes results from all lines of business within
the segment. The Adjusted EBITDA also includes the impact of
Humana’s 40% minority interest in Kindred at Home and the strategic
partnership with Welsh, Carson, Anderson & Stowe (WCAS) to
develop and operate senior-focused, payor-agnostic, primary care
centers.
(f) FY 2020 Adjusted EPS projections
exclude the following:
- Amortization expense for identifiable intangibles of
approximately $0.49 per diluted common share.
- Put/call valuation adjustments of $0.40 per diluted common
share related to Humana's non-consolidating minority interest
investments. FY20 GAAP EPS guidance excludes the impact of future
value changes of put/call options related to Humana’s
non-consolidating minority interest investments. The future value
change of these put/call options cannot be estimated.
(g) FY 2019 Adjusted results exclude the
following:
- Amortization expense for identifiable intangibles of
approximately $70 million pretax, or $0.40 per diluted common
share.
- Put/call valuation adjustments of approximately $506 million,
or $2.89 per diluted common share, associated with Humana’s
non-consolidating minority interest investments.
- Expense associated with involuntary workforce reduction of
approximately $47 million pretax, or $0.26 per diluted common
share.
Cautionary Statement
This news release includes forward-looking statements regarding
Humana within the meaning of the Private Securities Litigation
Reform Act of 1995. When used in investor presentations, press
releases, Securities and Exchange Commission (SEC) filings, and in
oral statements made by or with the approval of one of Humana’s
executive officers, the words or phrases like “expects,”
“believes,” “anticipates,” “intends,” “likely will result,”
“estimates,” “projects” or variations of such words and similar
expressions are intended to identify such forward-looking
statements.
These forward-looking statements are not guarantees of future
performance and are subject to risks, uncertainties, and
assumptions, including, among other things, information set forth
in the “Risk Factors” section of the company’s SEC filings, a
summary of which includes but is not limited to the following:
- If Humana does not design and price its products properly and
competitively, if the premiums Humana receives are insufficient to
cover the cost of healthcare services delivered to its members, if
the company is unable to implement clinical initiatives to provide
a better healthcare experience for its members, lower costs and
appropriately document the risk profile of its members, or if its
estimates of benefits expense are inadequate, Humana’s
profitability could be materially adversely affected. Humana
estimates the costs of its benefit expense payments, and designs
and prices its products accordingly, using actuarial methods and
assumptions based upon, among other relevant factors, claim payment
patterns, medical cost inflation, and historical developments such
as claim inventory levels and claim receipt patterns. The company
continually reviews estimates of future payments relating to
benefit expenses for services incurred in the current and prior
periods and makes necessary adjustments to its reserves, including
premium deficiency reserves, where appropriate. These estimates,
however, involve extensive judgment, and have considerable inherent
variability because they are extremely sensitive to changes in
claim payment patterns and medical cost trends, so any reserves the
company may establish, including premium deficiency reserves, may
be insufficient.
- If Humana fails to effectively implement its operational and
strategic initiatives, particularly its Medicare initiatives and
state-based contract strategy, the company’s business may be
materially adversely affected, which is of particular importance
given the concentration of the company’s revenues in these
products. In addition, there can be no assurances that the company
will be successful in maintaining or improving its Star ratings in
future years.
- If Humana fails to properly maintain the integrity of its data,
to strategically implement new information systems, to protect
Humana’s proprietary rights to its systems, or to defend against
cyber-security attacks or prevent other privacy or data security
incidents that result in security breaches that disrupt our
operations or in the unintended dissemination of sensitive personal
information or proprietary or confidential information, the
company’s business may be materially adversely affected.
- Humana is involved in various legal actions, or disputes that
could lead to legal actions (such as, among other things, provider
contract disputes and qui tam litigation brought by individuals on
behalf of the government), governmental and internal
investigations, and routine internal review of business processes
any of which, if resolved unfavorably to the company, could result
in substantial monetary damages or changes in its business
practices. Increased litigation and negative publicity could also
increase the company’s cost of doing business.
- As a government contractor, Humana is exposed to risks that may
materially adversely affect its business or its willingness or
ability to participate in government healthcare programs including,
among other things, loss of material government contracts,
governmental audits and investigations, potential inadequacy of
government determined payment rates, potential restrictions on
profitability, including by comparison of profitability of the
company’s Medicare Advantage business to non-Medicare Advantage
business, or other changes in the governmental programs in which
Humana participates. Changes to the risk-adjustment model utilized
by CMS to adjust premiums paid to Medicare Advantage, or MA, plans
according to the health status of covered members, including
proposed changes to the methodology used by CMS for risk adjustment
data validation audits that fail to address adequately the
statutory requirement of actuarial equivalence, if implemented,
could have a material adverse effect on our operating results,
financial position and cash flows.
- Humana's business activities are subject to substantial
government regulation. New laws or regulations, or legislative,
judicial, or regulatory changes in existing laws or regulations or
their manner of application could increase the company's cost of
doing business and have a material adverse effect on Humana’s
results of operations (including restricting revenue, enrollment
and premium growth in certain products and market segments,
restricting the company’s ability to expand into new markets,
increasing the company’s medical and operating costs by, among
other things, requiring a minimum benefit ratio on insured
products, lowering the company’s Medicare payment rates and
increasing the company’s expenses associated with a non-deductible
health insurance industry fee and other assessments); the company’s
financial position (including the company’s ability to maintain the
value of its goodwill); and the company’s cash flows.
- Humana’s failure to manage acquisitions, divestitures and other
significant transactions successfully may have a material adverse
effect on the company’s results of operations, financial position,
and cash flows.
- If Humana fails to develop and maintain satisfactory
relationships with the providers of care to its members, the
company’s business may be adversely affected.
- Humana’s pharmacy business is highly competitive and subjects
it to regulations in addition to those the company faces with its
core health benefits businesses.
- Changes in the prescription drug industry pricing benchmarks
may adversely affect Humana’s financial performance.
- If Humana does not continue to earn and retain purchase
discounts and volume rebates from pharmaceutical manufacturers at
current levels, Humana’s gross margins may decline.
- Humana’s ability to obtain funds from certain of its licensed
subsidiaries is restricted by state insurance regulations.
- Downgrades in Humana’s debt ratings, should they occur, may
adversely affect its business, results of operations, and financial
condition.
- The securities and credit markets may experience volatility and
disruption, which may adversely affect Humana’s business.
- The spread of, and response to, the novel coronavirus, or
COVID-19, underscores certain risks Humana faces, including those
discussed above, and the rapid development and fluidity of this
situation precludes any prediction as to the ultimate adverse
impact to Humana of COVID-19.
In December 2019, a novel strain of
coronavirus (COVID-19) was reported to have surfaced in Wuhan,
China. COVID-19 has since spread to over 200 countries, including
every state in the United States. On March 11, 2020 the World
Health Organization declared COVID-19 a pandemic, and on March 13,
2020 the United States declared a national emergency with respect
to COVID-19.
Governmental and non-governmental
organizations may not effectively combat the spread and severity of
COVID-19, increasing the potential for harm for Humana’s members.
If the spread of COVID-19 is not contained, the premiums the
company charges may prove to be insufficient to cover the cost of
health care services delivered to its members, which may increase
significantly as a result of higher utilization rates of medical
facilities and services and other increases in associated hospital
and pharmaceutical costs. Over time, Humana may also experience
increased costs or decreased revenues if, as a result of the
company’s members being unable to see their providers due to
actions taken to mitigate the spread of COVID-19, Humana is unable
to implement clinical initiatives to manage health care costs and
chronic conditions of its members, and appropriately document their
risk profiles. In addition, Humana is offering its members expanded
benefit coverage, such as providing full coverage for COVID-19
diagnostic testing and treatment, certain additional coverages have
been mandated by governmental action, and Humana is taking actions
designed to help provide financial and administrative relief for
the health care provider community. Such measures and any further
steps taken by Humana, or governmental action, to continue to
respond to and address the ongoing impact of COVID-19, including
further expansion or modification of the services delivered to its
members, the adoption or modification or regulatory requirements
associated with those services and the costs and challenges
associated with ensuring timely compliance with such requirements,
further relief for the health care provider community, or in
connection with the relaxation of stay-at-home and physical
distancing orders and other restrictions on movement and economic
activity, including the potential for widespread testing as a
component of lifting these measures, could adversely impact the
company’s profitability.
The spread and impact of COVID-19, or actions
taken to mitigate this spread, could have material and adverse
effects on Humana’s ability to operate effectively, including as a
result of the complete or partial closure of facilities or labor
shortages. Disruptions in public and private infrastructure,
including communications, availability of in-person sales and
marketing channels, financial services and supply chains, could
materially and adversely disrupt the company’s normal business
operations. Humana has transitioned a significant subset of its
employee population to a remote work environment in an effort to
mitigate the spread of COVID-19, as have a number of the company’s
third-party service providers, which may exacerbate certain risks
to Humana’s business, including an increased demand for information
technology resources, increased risk of phishing and other
cybersecurity attacks, and increased risk of unauthorized
dissemination of sensitive personal information or proprietary or
confidential information about the company or its members or other
third-parties. The outbreak of COVID-19 has severely impacted
global economic activity, including the businesses of some of
Humana’s commercial customers, and caused significant volatility
and negative pressure in the financial markets. In addition to
disrupting Humana’s operations, these developments may adversely
affect the timing of commercial customer premium collections and
corresponding claim payments, the value of the company’s investment
portfolio, or future liquidity needs.
The rapid development and fluidity of this
situation precludes any prediction as to the ultimate adverse
impact to Humana of COVID-19. Humana is continuing to monitor the
spread of COVID-19, changes to the company’s benefit coverages, the
ongoing costs and business impacts of dealing with COVID-19,
including the potential costs and impacts associated with lifting,
or reimposing restrictions on movement and economic activity and
ultimately a vaccine, and related risks. The magnitude and duration
of the pandemic and its impact on Humana’s business, results of
operations, financial position, and cash flows is uncertain as this
continues to evolve globally, but such impacts could be material to
the company’s business, results of operations, financial position
and cash flows.
In making forward-looking statements, Humana is not undertaking
to address or update them in future filings or communications
regarding its business or results. In light of these risks,
uncertainties, and assumptions, the forward-looking events
discussed herein may or may not occur. There also may be other
risks that the company is unable to predict at this time. Any of
these risks and uncertainties may cause actual results to differ
materially from the results discussed in the forward-looking
statements.
Humana advises investors to read the following documents as
filed by the company with the SEC for further discussion both of
the risks it faces and its historical performance:
- Form 10-K for the year ended December 31, 2019;
- Form 10-Q for the quarter ended March 31, 2020; and
- Form 8-Ks filed during 2020.
About Humana
Humana Inc. (NYSE: HUM) is committed to helping our millions of
medical and specialty members achieve their best health. Our
successful history in care delivery and health plan administration
is helping us create a new kind of integrated care with the power
to improve health and well-being and lower costs. Our efforts are
leading to a better quality of life for people with Medicare,
families, individuals, military service personnel, and communities
at large.
To accomplish that, we support physicians and other health care
professionals as they work to deliver the right care in the right
place for their patients, our members. Our range of clinical
capabilities, resources and tools – such as in-home care,
behavioral health, pharmacy services, data analytics and wellness
solutions – combine to produce a simplified experience that makes
health care easier to navigate and more effective.
More information regarding Humana is available to investors via
the Investor Relations page of the company’s website at humana.com,
including copies of:
- Annual reports to stockholders
- Securities and Exchange Commission filings
- Most recent investor conference presentations
- Quarterly earnings news releases and conference calls
- Calendar of events
- Corporate Governance information
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200805005249/en/
Amy Smith Humana Investor Relations (502) 580-2811 e-mail:
Amysmith@humana.com
Kelley Murphy Humana Corporate Communications (502) 224-1755
e-mail: Kmurphy26@humana.com
Humana (NYSE:HUM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Humana (NYSE:HUM)
Historical Stock Chart
From Apr 2023 to Apr 2024